Clinical characteristics and outcomes of COVID-19 in a low-prevalence, well resourced setting, Sydney, Australia.


Journal

Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952

Informations de publication

Date de publication:
Oct 2021
Historique:
revised: 21 06 2021
received: 27 02 2021
accepted: 22 06 2021
pubmed: 7 7 2021
medline: 26 10 2021
entrez: 6 7 2021
Statut: ppublish

Résumé

The Northern Sydney Local Health District was one of the first health regions to be affected by COVID-19 in Australia. To describe the clinical characteristics, risk factors and outcomes in our low-prevalence Australian population. This is a retrospective analysis of 517 laboratory-confirmed COVID-19 cases between January and June 2020. Patient information was collected as part of routine care within the COVID-19 Virtual Hospital system. Outcomes examined were death, recovery at 30 days and intensive care unit (ICU) admission. The case fatality rate was 1.8%. Multivariate analysis showed factors independently associated with death, composite outcome of death/ICU admission or incomplete recovery at 30 days were age >80 years and presence of two or more comorbidities. Most cases acquired COVID-19 through international (50.9%) or cruise ship travel (9.1%). Healthcare workers comprised 12.8% of the cohort and represented a disproportionately high percentage of the 'unknown' source group (27.6%). The median incubation period was 5 days (interquartile range 3-8); one patient had an incubation period of 15 days. Hospitalisation was required in 11.8%, ICU admission in 2.1% and ventilation in 1.4%. A Radiographic Assessment of Lung Oedema score on chest X-ray of >10 was independently associated with death. In this low prevalence, well resourced Australian setting, we report an overall low mortality. Factors associated with adverse patient outcomes on multivariate analysis were age greater than 80 and the presence of two or more comorbidities. These data can assist in early risk stratification of COVID-19 patients, and in surge capacity planning for hospitals.

Sections du résumé

BACKGROUND BACKGROUND
The Northern Sydney Local Health District was one of the first health regions to be affected by COVID-19 in Australia.
AIMS OBJECTIVE
To describe the clinical characteristics, risk factors and outcomes in our low-prevalence Australian population.
METHODS METHODS
This is a retrospective analysis of 517 laboratory-confirmed COVID-19 cases between January and June 2020. Patient information was collected as part of routine care within the COVID-19 Virtual Hospital system. Outcomes examined were death, recovery at 30 days and intensive care unit (ICU) admission.
RESULTS RESULTS
The case fatality rate was 1.8%. Multivariate analysis showed factors independently associated with death, composite outcome of death/ICU admission or incomplete recovery at 30 days were age >80 years and presence of two or more comorbidities. Most cases acquired COVID-19 through international (50.9%) or cruise ship travel (9.1%). Healthcare workers comprised 12.8% of the cohort and represented a disproportionately high percentage of the 'unknown' source group (27.6%). The median incubation period was 5 days (interquartile range 3-8); one patient had an incubation period of 15 days. Hospitalisation was required in 11.8%, ICU admission in 2.1% and ventilation in 1.4%. A Radiographic Assessment of Lung Oedema score on chest X-ray of >10 was independently associated with death.
CONCLUSIONS CONCLUSIONS
In this low prevalence, well resourced Australian setting, we report an overall low mortality. Factors associated with adverse patient outcomes on multivariate analysis were age greater than 80 and the presence of two or more comorbidities. These data can assist in early risk stratification of COVID-19 patients, and in surge capacity planning for hospitals.

Identifiants

pubmed: 34228387
doi: 10.1111/imj.15445
pmc: PMC8447053
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1605-1613

Informations de copyright

© 2021 Royal Australasian College of Physicians.

Références

Intern Med J. 2020 Oct;50(10):1271-1273
pubmed: 32945610
Radiol Med. 2020 Aug;125(8):730-737
pubmed: 32519256
Intern Med J. 2020 Sep;50(9):1146-1150
pubmed: 32761863
Intern Med J. 2021 Mar;51(3):334-340
pubmed: 33629801
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
Med J Aust. 2021 Jan;214(1):23-30
pubmed: 33325070
J Med Internet Res. 2021 Mar 9;23(3):e21064
pubmed: 33687341
Int J Infect Dis. 2021 Jan;102:32-36
pubmed: 33039607
Clin Microbiol Infect. 2021 Jan;27(1):19-27
pubmed: 32860962
J Med Virol. 2020 Oct;92(10):1902-1914
pubmed: 32293716
BMJ. 2020 May 22;369:m1985
pubmed: 32444460
Intern Med J. 2021 Feb;51(2):189-198
pubmed: 33631864
BMJ Open. 2020 Aug 16;10(8):e039652
pubmed: 32801208
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Med Mal Infect. 2020 Aug;50(5):436-439
pubmed: 32305563
J Gen Intern Med. 2020 May;35(5):1545-1549
pubmed: 32133578
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Med J Aust. 2021 Apr;214(7):332-332.e1
pubmed: 33713455
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076

Auteurs

Emily Shiel (E)

Department of Microbiology and Infectious Diseases, Royal North Shore Hospital, Sydney, New South Wales, Australia.

Spiros Miyakis (S)

Department of Infectious Diseases, Wollongong Hospital, Wollongong, New South Wales, Australia.

Elaine Tennant (E)

Department of Infectious Diseases, Northern Sydney Local Health District, Sydney, New South Wales, Australia.

Shelanah Fernando (S)

Department of Infectious Diseases, Northern Sydney Local Health District, Sydney, New South Wales, Australia.

Alice Kizny-Gordon (A)

Department of Microbiology, NSW Health Pathology, Sydney, New South Wales, Australia.

Bryant Koh (B)

Department of Microbiology, NSW Health Pathology, Sydney, New South Wales, Australia.

Michael Findlay (M)

Department of Microbiology and Infectious Diseases, Royal North Shore Hospital, Sydney, New South Wales, Australia.

Katherine Garnham (K)

Department of Microbiology, NSW Health Pathology, Sydney, New South Wales, Australia.

Shravya Pilli (S)

Department of Microbiology and Infectious Diseases, Royal North Shore Hospital, Sydney, New South Wales, Australia.

Hayden Segboer (H)

Department of Microbiology and Infectious Diseases, Royal North Shore Hospital, Sydney, New South Wales, Australia.

Jo Tallon (J)

Department of Infection Control, Royal North Shore Hospital, Sydney, New South Wales, Australia.

Joanna Kao (J)

Department of Radiology, Royal North Shore Hospital, Sydney, New South Wales, Australia.

Anne Miller (A)

Department of Radiology, Royal North Shore Hospital, Sydney, New South Wales, Australia.

Tim Shore (T)

Department of Radiology, Royal North Shore Hospital, Sydney, New South Wales, Australia.

Richard Maher (R)

Department of Radiology, Royal North Shore Hospital, Sydney, New South Wales, Australia.

Mark Telford (M)

Department of Nursing and Midwifery, Northern Sydney Local Health District, Sydney, New South Wales, Australia.

Kate Barclay (K)

Department of Respiratory Medicine, Northern Beaches Hospital, Sydney, New South Wales, Australia.

Ben Harris (B)

Department of Respiratory Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia.

James Newcombe (J)

Department of Microbiology and Infectious Diseases, NSW Health Pathology, Northern Sydney Local Health District, Sydney, New South Wales, Australia.

Bernie Hudson (B)

Department of Microbiology and Infectious Diseases, NSW Health Pathology, Northern Sydney Local Health District, Sydney, New South Wales, Australia.

Mel Figtree (M)

Department of Microbiology and Infectious Diseases, NSW Health Pathology, Northern Sydney Local Health District, Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH